Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.3K
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

479
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
479
Human Genetics01:28

Human Genetics

928
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
928
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

2.6K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.6K
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

1.4K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
1.4K
Genomics02:02

Genomics

38.2K
Genomics is the science of genomes: it is the study of all the genetic material of an organism. In humans, the genome consists of information carried in 23 pairs of chromosomes in the nucleus, as well as mitochondrial DNA. In genomics, both coding and non-coding DNA is sequenced and analyzed. Genomics allows a better understanding of all living things, their evolution, and their diversity. It has a myriad of uses: for example, to build phylogenetic trees, to improve productivity and...
38.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PharmVar GeneFocus: CYP1A2-Clinical Impact, Genetic Variation, and Updated Nomenclature.

Clinical pharmacology and therapeutics·2026
Same author

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of 5-HT<sub>3</sub> Receptor Antagonists: 2026 Update.

Clinical pharmacology and therapeutics·2026
Same author

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 Update.

Clinical pharmacology and therapeutics·2026
Same author

PharmVar GeneFocus: NAT2-Genetic Variation and Updated Nomenclature.

Clinical pharmacology and therapeutics·2025
Same author

An Update to the Clinical Pharmacogenetics Implementation Consortium (CPIC) SLCO1B1 Allele Functionality Table Leveraging Evidence from Participants of Predominantly Sub-Saharan African Ancestry.

Clinical pharmacology and therapeutics·2025
Same author

Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy.

Clinical pharmacology and therapeutics·2025

Related Experiment Video

Updated: Oct 30, 2025

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems
05:47

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems

Published on: June 13, 2025

794

An Evidence-Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine.

Michelle Whirl-Carrillo1, Rachel Huddart1, Li Gong1

  • 1Department of Biomedical Data Science, School of Medicine, Stanford University, Stanford, California, USA.

Clinical Pharmacology and Therapeutics
|July 3, 2021
PubMed
Summary

A new scoring system automates the assignment of evidence levels for pharmacogenomic (PGx) clinical annotations in PharmGKB. This enhances consistency and transparency in evaluating variant-drug associations for improved PGx data reliability.

More Related Videos

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.9K
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

34.2K

Related Experiment Videos

Last Updated: Oct 30, 2025

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems
05:47

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems

Published on: June 13, 2025

794
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.9K
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

34.2K

Area of Science:

  • Pharmacogenomics
  • Biomedical Informatics

Background:

  • Clinical annotations in the Pharmacogenomics Knowledgebase (PharmGKB) summarize variant-drug associations and are assigned a Level of Evidence (LOE).
  • Maintaining consistency in LOE assignment becomes challenging as more evidence is curated by multiple curators over time.

Purpose of the Study:

  • To develop and implement an automated scoring system for consistent and reproducible LOE assignment to PharmGKB clinical annotations.
  • To improve the transparency and robustness of pharmacogenomic data interpretation.

Main Methods:

  • A scoring system was developed to automate LOE assignment based on attributes of variant annotations (e.g., study size, P value, association findings).
  • Scores from clinical guidelines and FDA-approved drug labels were also incorporated.
  • Scores of all attached annotations are summed to calculate a total score, which determines the clinical annotation's LOE.

Main Results:

  • The scoring system automates LOE assignment, increasing transparency, consistency, and reproducibility.
  • Standardized writing of clinical annotations combined with the scoring system ensures PharmGKB remains a reliable source of pharmacogenomic information.

Conclusions:

  • The automated scoring system effectively standardizes LOE assignment for PharmGKB clinical annotations.
  • This system enhances the reliability and usability of pharmacogenomic data for clinical decision-making.